Comparative effects of Lunelle(TM) Monthly Contraceptive Injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum® 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic) on lipid profiles

Contraception

Volumn 61, Issue 1, 2000, Pages 51-59

  Cromie, Matthew A ^a   Maile, Marie H ^a   Wajszczuk, Charles P ^a  

^a PFIZER INC   (United States)

Author keywords

Estradiol cypionate; Ethinyl estradiol; Lipid profiles; Lune(TM); Lunella(TM); Lunelle(TM); Medroxyprogesterone acetate; Monthly contraceptive injection; MPA E2C; Norethindrone; Oral contraceptive; Ortho Novum 7 7 7

Indexed keywords

ESTRADIOL CIPIONATE; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ETHINYLESTRADIOL PLUS NORETHISTERONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; SCREENING;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; ESTRADIOL; FEMALE; HUMANS; LIPIDS; MEDROXYPROGESTERONE 17-ACETATE; MESTRANOL; NORETHINDRONE; TRIGLYCERIDES;

EID: 0034103474     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00114-6     Document Type: Article

References (21)

1. American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas: American Heart Association, 1998.
2. Jacobs D.R. Jr, Mebane I.L., Bangdiwala S.I., et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 131:1990;32-47.
3. Bass K.M., Newschaffer C.J., Klag M.J., Bush T.L. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 153:1993;2209-2216.
4. Kannel W.B. Metabolic risk factors for coronary heart disease in women perspective from the Framingham Study. Am Heart J. 114:1987;413-419.
5. Castelli W.P. The triglyceride issue a view from Framingham. Am Heart J. 112:1986;432-437.
6. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 3:1996;213-219.
7. Gianturco S., Bradley W.A. Triglyceride-rich lipoproteins and their role in atherogenesis. Curr Opin Lipidol. 2:1991;324-328.
8. Crook D., Godsland I. Safety evaluation of modern oral contraceptives effects on lipoprotein and carbohydrate metabolism. Contraception. 57:1998;189-201.
9. Castelli W.P., Anderson K., Wilson P.W.F., Levy D. Lipids and risk of coronary heart disease The Framingham Study. Ann Epidemiol. 2:1992;23-28.
10. Grover S.A., Palmer C.S., Coupal L. Serum lipid screening to identify high-risk individuals for coronary death the results of the Lipid Research Clinics Prevalence Cohort. Arch Intern Med. 154:1994;679-684.
11. Kostner G.M. Apolipoproteins and lipoproteins of human plasma significance in health and in disease. Adv Lipid Res. 20:1983;1-43.
12. WHO Scientific Group. Cardiovascular disease and steroid hormone contraception. WHO Technical Report Series No. 877. Geneva: World Health Organization, 1998.
13. Farley T.M.M., Collins J., Schlesselman J.J. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception. 57:1998;211-230.
14. Mishell DR Jr, Stenchever MA, Droegemueller W, Herbst AL. Comprehensive Gynecology. 3rd ed. St. Louis: Mosby-Year Book, 1997:291-305.
15. Krauss R.M., Burkman R.T. Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynecol. 167:1992;1177-1184.
16. Crook D., Godsland I.F., Wynn V. Oral contraceptives and coronary heart disease modulation of glucose tolerance and plasma lipid risk factors by progestins. Am J Obstet Gynecol. 158:1988;1612-1620.
17. Godsland I.F., Crook D., Simpson R., et al. Effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 323:1990;1375-1381.
18. Notelovitz M., Feldman E.B., Gillespy M., Gudat J. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives a controlled, comparative, 12-month clinical trial. Am J Obstet Gynecol. 160:1989;1269-1280.
19. Miller G.J. Hyperlipidaemia and hypercoagulability. Prog Lipid Res. 32:1993;61-69.
20. Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna® and Cyclofem®) on lipid and lipoprotein metabolism. Contraception. 56:1997;193-207.
21. Kaunitz AM, Garceau RJ, Cromie MA, and the Lunelle™ Study Group. Comparative safety, efficacy, and cycle control of Lunelle Monthly Contraceptive Injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum® 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Contraception 1999;60:179-187.